Poly(ADP-ribose)polymerase inhibition decreases angiogenesis

Mohanraj Rajesh, Partha Mukhopadhyay, Grzegorz Godlewski, Sándor Bátkai, G. Haskó, Lucas Liaudet, Pál Pacher

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Inhibitors of poly(ADP-ribose)polymerase (PARP), a nuclear enzyme involved in regulating cell death and cellular responses to DNA repair, show considerable promise in the treatment of cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation. We have recently demonstrated that PARP inhibition with 3-aminobenzamide or PJ-34 reduced vascular endothelial growth factor (VEGF)-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Here, we show dose-dependent reduction of VEGF- and basic fibroblast growth factor (bFGF)-induced proliferation, migration, and tube formation of HUVECs in vitro by two potent PARP inhibitors 5-aminoisoquinolinone-hydrochloride (5-AIQ) and 1,5-isoquinolinediol (IQD). Moreover, PARP inhibitors prevented the sprouting of rat aortic ring explants in an ex vivo assay of angiogenesis. These results establish the novel concept that PARP inhibitors have antiangiogenic effects, which may have tremendous clinical implications for the treatment of various cancers, tumor metastases, and certain retinopathies.

Original languageEnglish
Pages (from-to)1056-1062
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume350
Issue number4
DOIs
Publication statusPublished - Dec 1 2006

Fingerprint

Poly(ADP-ribose) Polymerases
Endothelial cells
Human Umbilical Vein Endothelial Cells
Vascular Endothelial Growth Factor A
Neoplasms
Fibroblast Growth Factor 2
Cell death
DNA Repair
Rats
Tumors
Assays
Repair
Cell Death
Radiation
Neoplasm Metastasis
Poly(ADP-ribose) Polymerase Inhibitors
DNA
Enzymes
In Vitro Techniques

Keywords

  • 1,5-Isoquinolinediol (IQD)
  • 5-Aminoisoquinolinone-hydrochloride (5-AIQ)
  • Angiogenesis
  • Aortic ring assay
  • Cancer
  • HUVEC
  • Migration
  • Poly(ADP-ribose)polymerase (PARP)
  • Proliferation
  • Tube formation

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Rajesh, M., Mukhopadhyay, P., Godlewski, G., Bátkai, S., Haskó, G., Liaudet, L., & Pacher, P. (2006). Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochemical and Biophysical Research Communications, 350(4), 1056-1062. https://doi.org/10.1016/j.bbrc.2006.09.160

Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. / Rajesh, Mohanraj; Mukhopadhyay, Partha; Godlewski, Grzegorz; Bátkai, Sándor; Haskó, G.; Liaudet, Lucas; Pacher, Pál.

In: Biochemical and Biophysical Research Communications, Vol. 350, No. 4, 01.12.2006, p. 1056-1062.

Research output: Contribution to journalArticle

Rajesh, M, Mukhopadhyay, P, Godlewski, G, Bátkai, S, Haskó, G, Liaudet, L & Pacher, P 2006, 'Poly(ADP-ribose)polymerase inhibition decreases angiogenesis', Biochemical and Biophysical Research Communications, vol. 350, no. 4, pp. 1056-1062. https://doi.org/10.1016/j.bbrc.2006.09.160
Rajesh, Mohanraj ; Mukhopadhyay, Partha ; Godlewski, Grzegorz ; Bátkai, Sándor ; Haskó, G. ; Liaudet, Lucas ; Pacher, Pál. / Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 350, No. 4. pp. 1056-1062.
@article{46f28b689dd44e66a1c8dea72c3d745b,
title = "Poly(ADP-ribose)polymerase inhibition decreases angiogenesis",
abstract = "Inhibitors of poly(ADP-ribose)polymerase (PARP), a nuclear enzyme involved in regulating cell death and cellular responses to DNA repair, show considerable promise in the treatment of cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation. We have recently demonstrated that PARP inhibition with 3-aminobenzamide or PJ-34 reduced vascular endothelial growth factor (VEGF)-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Here, we show dose-dependent reduction of VEGF- and basic fibroblast growth factor (bFGF)-induced proliferation, migration, and tube formation of HUVECs in vitro by two potent PARP inhibitors 5-aminoisoquinolinone-hydrochloride (5-AIQ) and 1,5-isoquinolinediol (IQD). Moreover, PARP inhibitors prevented the sprouting of rat aortic ring explants in an ex vivo assay of angiogenesis. These results establish the novel concept that PARP inhibitors have antiangiogenic effects, which may have tremendous clinical implications for the treatment of various cancers, tumor metastases, and certain retinopathies.",
keywords = "1,5-Isoquinolinediol (IQD), 5-Aminoisoquinolinone-hydrochloride (5-AIQ), Angiogenesis, Aortic ring assay, Cancer, HUVEC, Migration, Poly(ADP-ribose)polymerase (PARP), Proliferation, Tube formation",
author = "Mohanraj Rajesh and Partha Mukhopadhyay and Grzegorz Godlewski and S{\'a}ndor B{\'a}tkai and G. Hask{\'o} and Lucas Liaudet and P{\'a}l Pacher",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.bbrc.2006.09.160",
language = "English",
volume = "350",
pages = "1056--1062",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Poly(ADP-ribose)polymerase inhibition decreases angiogenesis

AU - Rajesh, Mohanraj

AU - Mukhopadhyay, Partha

AU - Godlewski, Grzegorz

AU - Bátkai, Sándor

AU - Haskó, G.

AU - Liaudet, Lucas

AU - Pacher, Pál

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Inhibitors of poly(ADP-ribose)polymerase (PARP), a nuclear enzyme involved in regulating cell death and cellular responses to DNA repair, show considerable promise in the treatment of cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation. We have recently demonstrated that PARP inhibition with 3-aminobenzamide or PJ-34 reduced vascular endothelial growth factor (VEGF)-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Here, we show dose-dependent reduction of VEGF- and basic fibroblast growth factor (bFGF)-induced proliferation, migration, and tube formation of HUVECs in vitro by two potent PARP inhibitors 5-aminoisoquinolinone-hydrochloride (5-AIQ) and 1,5-isoquinolinediol (IQD). Moreover, PARP inhibitors prevented the sprouting of rat aortic ring explants in an ex vivo assay of angiogenesis. These results establish the novel concept that PARP inhibitors have antiangiogenic effects, which may have tremendous clinical implications for the treatment of various cancers, tumor metastases, and certain retinopathies.

AB - Inhibitors of poly(ADP-ribose)polymerase (PARP), a nuclear enzyme involved in regulating cell death and cellular responses to DNA repair, show considerable promise in the treatment of cancer both in monotherapy as well as in combination with chemotherapeutic agents and radiation. We have recently demonstrated that PARP inhibition with 3-aminobenzamide or PJ-34 reduced vascular endothelial growth factor (VEGF)-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro. Here, we show dose-dependent reduction of VEGF- and basic fibroblast growth factor (bFGF)-induced proliferation, migration, and tube formation of HUVECs in vitro by two potent PARP inhibitors 5-aminoisoquinolinone-hydrochloride (5-AIQ) and 1,5-isoquinolinediol (IQD). Moreover, PARP inhibitors prevented the sprouting of rat aortic ring explants in an ex vivo assay of angiogenesis. These results establish the novel concept that PARP inhibitors have antiangiogenic effects, which may have tremendous clinical implications for the treatment of various cancers, tumor metastases, and certain retinopathies.

KW - 1,5-Isoquinolinediol (IQD)

KW - 5-Aminoisoquinolinone-hydrochloride (5-AIQ)

KW - Angiogenesis

KW - Aortic ring assay

KW - Cancer

KW - HUVEC

KW - Migration

KW - Poly(ADP-ribose)polymerase (PARP)

KW - Proliferation

KW - Tube formation

UR - http://www.scopus.com/inward/record.url?scp=33750046338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750046338&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.09.160

DO - 10.1016/j.bbrc.2006.09.160

M3 - Article

C2 - 17046715

AN - SCOPUS:33750046338

VL - 350

SP - 1056

EP - 1062

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -